US 7,541,031 B2
	Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα
Jochen G. Salfeld, North Grafton, Mass. (US); Deborah J. Allen, London (United Kingdom); Zehra Kaymakcalan, Westborough, Mass. (US); Boris Labkovsky, Marlborough, Mass. (US); John A. Mankovich, Andover, Mass. (US); Brian T. McGuinness, Cambridge (United Kingdom); Andrew J. Roberts, Cambridge (United Kingdom); Paul Sakorafas, Newton Highlands, Mass. (US); Hendricus R. J. M. Hoogenboom, Hasselt (Belgium); David Schoenhaut, Clifton, N.J. (US); Tristan J. Vaughan, Cambridge (United Kingdom); Michael White, Framingham, Mass. (US); and Alison J. Wilton, Cambridge (United Kingdom)
Assigned to Abbott Biotechnology Ltd., (Bermuda)
Filed on Apr. 17, 2007, as Appl. No. 11/787,901.
Application 11/787901 is a continuation of application No. 09/801185, filed on Mar. 07, 2001, granted, now 7,223,394.
Application 09/801185 is a continuation of application No. 09/125098, granted, now 6,258,562, previously published as PCT/US97/02219, filed on Feb. 10, 1997.
Application 09/125098 is a continuation in part of application No. 08/599226, filed on Feb. 09, 1996, granted, now 6,090,382.
Claims priority of provisional application 60/031476, filed on Nov. 25, 1996.
Prior Publication US 2007/0249813 A1, Oct. 25, 2007
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 31/495 (2006.01)

U.S. Cl. 424—142.1  [424/145.1; 424/158.1; 424/810; 514/249]

11 Claims

1. A method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1×10−8 M or less and a Koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less, and neutralizes TNFα-induced cellular activation in a standard in vitro assay for TNRα-induced ELAM-1 expression on human umbilical vein endothelial cells (HUVEC).